Edition:
United Kingdom

Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

4.90USD
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
$4.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,929
52-wk High
$7.59
52-wk Low
$2.99

Latest Key Developments (Source: Significant Developments)

Cerecor Inc - Files For Offering Shares Of Common Stock, Size Not Disclosed - SEC Filing
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Cerecor Inc ::CERECOR INC - FILES FOR OFFERING SHARES OF COMMON STOCK, SIZE NOT DISCLOSED - SEC FILING.  Full Article

Cerecor Receives Fast Track Designation from FDA for CERC-801 For The Treatment Of PGM1 Deficiency
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Cerecor Inc ::CERECOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR CERC-801 FOR THE TREATMENT OF PGM1 DEFICIENCY.  Full Article

FDA Accepts IND Application For Cerecor’S Investigational Drug For The Treatment Of PGM1 Deficiency
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Cerecor Inc ::FDA ACCEPTS IND APPLICATION FOR CERECOR’S INVESTIGATIONAL DRUG CERC-801 FOR THE TREATMENT OF PGM1 DEFICIENCY.CERECOR INC - FDA HAS ACCEPTED ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CERC-801.  Full Article

Cerecor Q4 Loss Per Share $0.11
Monday, 2 Apr 2018 

April 2 (Reuters) - Cerecor Inc ::REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017.Q4 LOSS PER SHARE $0.11.SEES FY 2018 REVENUE MORE THAN $15 MILLION.Q4 REVENUE $2.2 MILLION.  Full Article

Cerecor Inc Appoints Peter Greenleaf CEO
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Cerecor Inc ::CERECOR APPOINTS PETER GREENLEAF AS CHIEF EXECUTIVE OFFICER.CERECOR - GREENLEAF MOST RECENTLY SERVED AS CHAIRMAN AND CEO OF SUCAMPO PHARMACEUTICALS.  Full Article

Cerecor To Acquire Avadel Pharmaceuticals' Pediatric Assets
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Cerecor Inc ::CERECOR TO ACQUIRE AVADEL PHARMACEUTICALS' PEDIATRIC ASSETS.TRANSACTION IS IMMEDIATELY ACCRETIVE TO REVENUE AND EARNINGS.WILL BUY AVADEL'S INTEREST IN AVADEL PEDIATRIC ASSETS FOR NOMINAL CASH PAYMENT.AVADEL IRELAND TO DEVELOP,PROVIDE CO WITH 4 STABLE PRODUCT FORMULATIONS OF CO'S CHOOSING UTILIZING PROPRIETARY LIQUITIME,MICROPUMP TECHNOLOGY.  Full Article

Cerecor announces leadership changes
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Cerecor Inc :Cerecor announces leadership changes.Cerecor Inc - ‍Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down​.Cerecor Inc - ‍Appoints Randal O. Jones and Robert C. Moscato, Jr. to board of directors​.Cerecor Inc - ‍ Names Robert Moscato as president and Chief Operating Officer​.Cerecor Inc - ‍Mariam Morris will continue as Cerecor's chief financial officer​.  Full Article

Cerecor reports Q3 earnings per share of $0.52
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Cerecor Inc ::Cerecor Inc reports third quarter 2017 financial results.Q3 earnings per share $0.52.As of Sept 30, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million​.Expect existing cash and cash equivalents, initial proceeds from Janssen sale will fund operating expenditures through at least 2018​.  Full Article

Cerecor Inc says Uli Hacksell retires as CEO, president
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Cerecor Inc :Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer.Cerecor Inc says John Kaiser, chief business officer of Cerecor, has been appointed interim chief executive officer.Cerecor Inc says board of directors has initiated a search for a permanent chief executive officer.Cerecor Inc says Hacksell will stay on as chairman of Cerecor's board.  Full Article

Cerecor Inc Q2 loss per share $0.14
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Cerecor Inc :Cerecor Inc reports second quarter 2017 financial results.Q2 loss per share $0.14.Q2 revenue $200,000.In August 2017, co sold its world-wide rights of CERC-501 to Janssen in exchange for an initial payment of $25 million​.Under agreement, Janssen will assume ongoing clinical trials and be responsible for any new development or commercialization of CERC-501..Expect existing cash & cash equivalents & proceeds from Janssen sale, to fund operating expenditure requirements through at least 2018.  Full Article